Canadian pharmaceutical seeks to conduct Covid-19 drug trials in Morocco

Canadian pharmaceutical seeks to conduct Covid-19 drug trials in Morocco
Tuesday 2 November 2021 - 13:36

Canadian pharmaceuticals manufacturer Resverlogix has begun ‘active discussions’ with Morocco’s Health Ministry, for possible Phase 2 clinical studies within national hospitals using apabetalone, Resverlogix’ first-in-class COVID-19 drug.

The President & CEO of Resverlogix, Donald J. McCaffrey, made the announcement on November 1, saying that “We are pleased to collaborate with the Kingdom of Morocco’s Ministry of Health under the leadership of Professor Bouchra Meddah, Director of Medicines and Pharmacy, for this possible launch.”

McCaffrey added that “it is imperative to clear hospital beds of COVID-19 patients to allow urgent surgeries and other necessities to take place, which will contribute to reopening and strengthening the economy in the Kingdom of Morocco.”

Professor Bouchra Meddah said Morocco is pleased to be collaborating with Resverlogix, and that it has followed the various scientific publications issued on these trials.

On October 12, Resverlogix obtained approval from the Canadian Health Research Ethics Board in the Biomedical Panel at the University of Alberta, to launch its clinical trial of the new COVID-19 treatment.

Apabetalone is the only current drug of its class to possess a well-established safety record in human trials.

According to the studies, apabetalone can potentially target the COVID-19 virus with a peculiar dual-mechanism, which prevents viral infections to cells and their replications, and stops runaway inflammatory reactions.

Study participants will be made up of patients hospitalized with confirmed COVID-19 cases.

Participants will either receive two daily doses of apabetalone for up to 4 weeks alongside standard care, compared to standard care alone.

Resverlogix aims for primary positive outcome measures so that the treatment can be included in the World Health Organization’s (WHO) Ordinal Scale for Clinical Improvement.

A total of 100 patients are expected to be enrolled at multiple sites in Canada and Brazil.

add your comment

Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.

Society
Morocco ranks sixth among main sources of new migrants to OECD countries in 2024
Sunday 15 November 2026 - 23:00

Morocco ranks sixth among main sources of new migrants to OECD countries in 2024

Economy
Lekjaa defends FIFA tax exemptions ahead of 2030 World Cup, rejects opposition proposals
Sunday 15 November 2026 - 21:00

Lekjaa defends FIFA tax exemptions ahead of 2030 World Cup, rejects opposition proposals

News
Moroccan lawyers announce nationwide strike over proposed profession bill
Sunday 15 November 2026 - 19:00

Moroccan lawyers announce nationwide strike over proposed profession bill

Sports
Morocco’s AS FAR women win third African Champions League title
Sunday 15 November 2026 - 18:00

Morocco’s AS FAR women win third African Champions League title